Arizona Bioscience News: PathogenDX raises $7.5M; Phoenix wearable-tech center opens; promising HonorHealth clinical trial

October 3, 2019

By Matt Ellsworth

Scottsdale bioscience firm gets $7.5M in funding to expand into new markets / KJZZ

Scottsdale-based PathogenDX Inc., whose technology tests for bacterial and fungal contaminants like E. coli contamination in six hours or less, has raised another $7.5 million to initiate food and agriculture testing.

New wearable tech center in midtown Phoenix to foster research and development / Phoenix Business Journal

The 5,000-square-foot WearTech Center at Park Central Mall, a collaboration of the Partnership for Economic Innovation, Arizona State University and Arizona’s state government, has opened to foster research, develop solutions and launch wearables companies.

HonorHealth pancreatic-cancer clinical trials seeing encouraging results / KJZZ

A pancreatic-cancer trial at the Virginia G. Piper Cancer Center at HonorHealth in Scottsdale is seeing positive responses from patients fighting a disease with very low survival rates.

Tucson Tech: Ideas meet money at annual pitch competition / Arizona Daily Star

The annual IdeaFunding pitch competition, part of the TenWest Impact Festival in Tucson, will feature an opportunity for bioscience and other startups to win cash and business services.

Tucson entrepreneur McCusker named state’s tech business leader of the year / Arizona Daily Star Tucson entrepreneur and UAVenture Capital CEO Fletcher McCusker has been named the 2019 Ed Denison Business Leader of the Year by the Arizona Technology Council and the Arizona Commerce Authority as part of the Governor’s Celebration of Innovation Awards.

Read more: UA-focused venture fund invests in three laser-tech startups

University of Arizona College of Medicine, Phoenix VA launch research on drug interaction / KJZZ

The University of Arizona College of Medicine – Phoenix is partnering with the Phoenix’s Veterans Affairs Health Care System to study how drugs interact, specifically among veterans, in a new program called Pharmacogenomics Action for Cancer Survivorship, or PHASER.

Sign up to receive Arizona Bioscience News weekly